[Prevalence of SARS-CoV-2 in children from a cohort of 2192 patients]

M Meyer1, E Rübsteck1, C Lehmann2

  • 1Medizinische Fakultät und Uniklinik Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universität zu Köln, Kerpener Str. 62, 50924 Köln, Deutschland.

Insights

This study found that 1.7% of children tested in Germany had SARS-CoV-2 infections, with most cases being mild or asymptomatic. These findings confirm that pediatric COVID-19 cases often present with less severe symptoms.

Area of Science:

  • Pediatric infectious diseases
  • Virology
  • Epidemiology

Context:

  • As of June 18, 2020, Germany reported over 187,000 SARS-CoV-2 cases, with 6.9% in individuals under 19.
  • Initial observations suggested children often present with asymptomatic or milder SARS-CoV-2 infections.
  • Understanding pediatric COVID-19 prevalence is crucial for public health strategies.

Purpose:

  • To determine the prevalence of SARS-CoV-2 infections in a pediatric cohort in Germany.
  • To characterize the clinical presentation and severity of COVID-19 in children.

Summary:

  • A retrospective analysis included 2192 children tested for SARS-CoV-2 between March 13 and June 18, 2020.
  • 37 children (1.7%) tested positive; 36 were suspected cases, and 28 were symptomatic (dry cough, runny nose, fever).
  • Three children required hospitalization, but none had severe disease; 3/505 at-risk children had asymptomatic/mild infections.

Impact:

  • This study confirms that children and adolescents frequently experience asymptomatic or mild courses of SARS-CoV-2 infection.
  • Findings suggest no significant underestimation of SARS-CoV-2 infections in this regional pediatric population.
  • Results contribute to the understanding of pediatric COVID-19 epidemiology and clinical outcomes.
Abstract

Related Concept Videos

Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.2K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
141
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
117
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
121